These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15032725)

  • 1. Property-based design of KDR kinase inhibitors.
    Fraley ME; Hoffman WF; Arrington KL; Hungate RW; Hartman GD; McFall RC; Coll KE; Rickert K; Thomas KA; McGaughey GB
    Curr Med Chem; 2004 Mar; 11(6):709-19. PubMed ID: 15032725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
    Wu Z; Fraley ME; Bilodeau MT; Kaufman ML; Tasber ES; Balitza AE; Hartman GD; Coll KE; Rickert K; Shipman J; Shi B; Sepp-Lorenzino L; Thomas KA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):909-12. PubMed ID: 15012992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.
    Fraley ME; Rubino RS; Hoffman WF; Hambaugh SR; Arrington KL; Hungate RW; Bilodeau MT; Tebben AJ; Rutledge RZ; Kendall RL; McFall RC; Huckle WR; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2002 Dec; 12(24):3537-41. PubMed ID: 12443771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
    Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.
    Bilodeau MT; Cunningham AM; Koester TJ; Ciecko PA; Coll KE; Huckle WR; Hungate RW; Kendall RL; McFall RC; Mao X; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2485-8. PubMed ID: 12852948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring novel KDR inhibitors based on pharmaco-informatics methodology.
    Kar RK; Suryadevara P; Sahoo BR; Sahoo GC; Dikhit MR; Das P
    SAR QSAR Environ Res; 2013; 24(3):215-34. PubMed ID: 23437769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
    Boyer SJ
    Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors.
    Akritopoulou-Zanze I; Darczak D; Sarris K; Phelan KM; Huth JR; Song D; Johnson EF; Jia Y; Djuric SW
    Bioorg Med Chem Lett; 2006 Jan; 16(1):96-9. PubMed ID: 16216502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
    Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
    Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
    Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.
    Fraley ME; Arrington KL; Hambaugh SR; Hoffman WF; Cunningham AM; Young MB; Hungate RW; Tebben AJ; Rutledge RZ; Kendall RL; Huckle WR; McFall RC; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2003 Sep; 13(18):2973-6. PubMed ID: 12941314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDR inhibitor with the intramolecular non-bonded interaction: conformation-activity relationships of novel indole-3-carboxamide derivatives.
    Honda T; Nagahara H; Mogi H; Ban M; Aono H
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1782-5. PubMed ID: 21324683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    Du J; Lei B; Qin J; Liu H; Yao X
    J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scoring of KDR kinase inhibitors: using interaction energy as a guide for ranking.
    McGaughey GB; Culberson JC; Feuston BP; Kreatsoulas C; Maiorov V; Shpungin J
    Mol Divers; 2006 Aug; 10(3):341-7. PubMed ID: 17004013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and strategies of VEGFR-2/KDR inhibitors.
    Huang L; Huang Z; Bai Z; Xie R; Sun L; Lin K
    Future Med Chem; 2012 Sep; 4(14):1839-52. PubMed ID: 23043480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
    Sun L; Liang C; Shirazian S; Zhou Y; Miller T; Cui J; Fukuda JY; Chu JY; Nematalla A; Wang X; Chen H; Sistla A; Luu TC; Tang F; Wei J; Tang C
    J Med Chem; 2003 Mar; 46(7):1116-9. PubMed ID: 12646019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.
    Choquette D; Teffera Y; Polverino A; Harmange JC
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4054-8. PubMed ID: 18573658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.